New US headquarters opened in Waltham, Massachusetts
Refeyn staff join mass photometry inventor Prof. Philip Kukura in cutting ribbon to Refeyn’s new US customer interaction center in Massachusetts’ Waltham Biotech Hub
User innovation takes center stage at 2024 Mass Photometry Summit
The remarkable evolution of mass photometry was celebrated at the annual mass photometry user summit. From prototype to commercially available instrument used in hundreds of laboratories, this innovative technology was on display at the third annual scientific meeting of this event – dedicated to mass photometry users and hosted by Refeyn. The event took place at Wylie Conference Center on May 22 in Beverly, Massachusetts, a coastal suburb of Boston, USA.
Refeyn appoints new Chief Marketing Officer
Refeyn is delighted to announce the appointment of Fiona Coats as Chief Marketing Officer, effective from June, 2024. Forming part of Refeyn’s executive team, Fiona will bring with her a wealth of experience from over 25 years in the biotechnology sector.
Refeyn strengthens capability with new US Headquarters in Boston area
New US customer interaction center opens in Massachusetts’ Waltham Biotech Hub with 3rd annual Mass Photometry Summit set to highlight latest advances
Expert interview on accelerating AAV development processes
ABL, an Institut Mérieux Company, is a distinguished contract development and manufacturing organization (CDMO) providing GMP viral vectors from early stage to market.
Refeyn’s new KaritroMP quickly analyzes large viral vectors
New macro mass photometer can assess the stability, quality, and purity of adenovirus and lentivirus vectors within just minutes
MassFerence P2 calibrator for AAV analytics with mass photometry
Refeyn is pleased to announce the expansion of the consumables portfolio for mass photometry. Refeyn has created a new product line of mass reference standards, MassFerence, which help streamline sample characterization with mass photometry.
A fresh look at protein aggregation using mass photometry
Neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, both involve an accumulation of protein aggregates [1],[2]. Monitoring and studying small oligomers, which are present in the early stages of disease, can be challenging, due to their transient and heterogeneous nature [1].
Analyze low-affinity interactions with MassFluidix® HC
New microfluidic system enhances protein analysis workflows for the study of weak protein-protein interactions by mass photometry
Refeyn announces appointment of a new CEO
Refeyn, a leading Life Science instrumentation company pioneering mass photometry, announced today that Gerry Mackay has been appointed the new CEO of the company effective January 1st, 2024.
